



163 146

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kathleen A. Elias

Attorney Docket No.: CYTOP002D1

Application No.: 10/082,036

Examiner: Unassigned

Filed: February 20, 2002

Group: 1631

Title: METHOD OF CHARACTERIZING
POTENTIAL THERAPEUTICS BY
DETERMINING CELL-CELL
INTERACTIONS

RECEIVED
MAR 24 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Commissioner for Patents, Washington DC 20231 on March 17, 2003.

Signed: _____

Agnes Spence

**INFORMATION DISCLOSURE STATEMENT
37 CFR §§1.56 AND 1.97(b)**

Commissioner for Patents
Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP002D1).

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP



Lauren L. Stevens, Ph.D.
Registration No. 36,691

P.O. Box 778
Berkeley, CA 94704-0778



Form 1449 (Rev. 11/99) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. CYTOP002D1 Applicant: Kathleen A. Elias Filing Date February 20, 2002	Application No.: 10/082,036 Group 1631
	<div style="text-align: right;"> RECEIVED MAR 24 2003 TECH CENTER 1600/2900 </div>	

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	A	5,326,691	07/05/94	Hozier			
	B	5,355,215	10/11/94	Schroeder et al.			

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	C	93/21511	28.10.93	PCT				
	D	94/11841	26.05.94	PCT				
	E	96/09605	28.03.96	PCT				
	F	97/43732	20.11.97	PCT				
	G	99/05323	04.02.99	PCT				
	H	00/70528	23/11/00	PCT				

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	I	Adams et al., "Cell patterning on glass and polymeric substrates" US Patent Application No. 60/138,119, filed June 7, 1999
	J	Kapur et al., "Design and Fabrication of Spatially Controlled Miniaturized Organ Systems from Stem Cells", US Patent Application No. 60/127,339, filed April 1, 1999
	K	Hofland et al., "Role of Tumor - Derived Fibroblasts in the Growth of Primary Cultures of Human Breast-Cancer Cells: Effects of Epidermal Growth Factor and the Somatostatin Analogue Octreotide", 1995, Int. J. Cancer: 60, 93-99.
	L	Stearns et al., "Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP) 2/MMP-9 Secretion", January 1999, Clinical Cancer Research, vol. 5 189-196.
	M	Takayama et al., "Patterning cells and their environments using multiple laminar fluid flows in capillary networks", May 1999, Proc. Natl., Acad. Sci. USA, vol. 96, pp. 5545-5548.
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.